GLP-1 drug shaping diabetes, obesity care, and cardiovascular risk
A wave of recent studies finds GLP-1 weight-loss drugs have variable social and employment impacts beyond health. Observational data hint at temporary gains in dating and job prospects for some women, while other analyses show no long-term causal effects. Experts call for individualized treatment and longer follow-up.
[Synopsis here]
A new weight‑loss pill version of semaglutide has launched in the UK for private prescriptions, offering an alternative to injections. The tablet requires strict dosing and a fasting routine and is not yet NHS‑funded. Several outlets warn about counterfeit pills as access broadens.
The wedding dress market is shifting as GLP-1 weight loss drugs become common among engaged couples. Designers report earlier fittings, changed guarantees, and rising alterations costs. Brides worry about weight loss before weddings, while sales staff push early purchases and flexible guarantees.
Vivani Medical and Novo Nordisk are exploring a long-acting semaglutide implant to maintain weight loss, potentially replacing frequent injections. The device aims to release medicine steadily for months, pending clinical and regulatory validation.
Novo Nordisk has filed a U.S. lawsuit accusing Eli Lilly of false advertising in nationwide campaigns for Zepbound and Mounjaro, arguing Lilly used outdated trial data to claim superiority. Lilly defends its ads, citing SURMOUNT-5 results and higher Wegovy doses, while Novo seeks a court order to halt campaigns and demand corrective advertising amid a fight for GLP-1 market dominance.